{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-008650","form_type":"8-K","ticker":"ABCL","cik":"0001703057","company_name":"AbCellera Biologics Inc.","filed_at":"2025-02-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.501665+00:00","generated_at":"2026-05-26T02:14:14.411078+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"AbCellera FY2024 revenue $28.8M (down 24%), net loss $0.55/share; plans Phase 1 for two programs in 2025","bullets":["Revenue $28.8M vs $38.0M in 2023; net loss $162.9M ($0.55 loss per share) vs $146.4M loss in 2023.","Cash, securities and non-dilutive govt funding total approx. $840M in available liquidity.","Cumulative partner program starts up to 96 (87 in 2023); 16 molecules in clinic (13 in 2023).","Plans to initiate Phase 1 trials for ABCL635 and ABCL575 and start clinical manufacturing facility in 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-008650","json":"https://secwatch.observer/filing/0001628280-25-008650.json","markdown":"https://secwatch.observer/filing/0001628280-25-008650.md","text":"https://secwatch.observer/filing/0001628280-25-008650.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1703057/000162828025008650/0001628280-25-008650-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1703057/000162828025008650/abcl-20250227.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T02:14:14.411078+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}